Yildirim Fatma, Karaman Irem, Yıldırım Mehmet, Karabacak Harun
General Surgery Intensive Care Unit, Department of Pulmonary and Critical Care Medicine, Dışkapı Yıldırım Beyazıt Research and Education Hospital, University of Health Sciences, Ankara, Türkiye.
School of Medicine, Bahçeşehir University, Istanbul, Türkiye.
Front Surg. 2024 May 9;11:1357492. doi: 10.3389/fsurg.2024.1357492. eCollection 2024.
The efficacy of non-invasive mechanical ventilation (NIMV) on the postoperative ARF is conflicting and the failure rate of NIMV in this patient population is high. In our study, we hypothesized that the use of dexmedetomidine during NIMV in major abdominal surgical patients can reduce NIMV failure without significant side affect.
Medical records of patients who underwent major abdominal surgery, admitted to our general surgery intensive care unit (ICU), developed postoperative ARF, received NIMV (with oro-nasal mask) and dexmedetomidine infusion were enrolled in this study. The infusion rate was adjusted to maintain a target sedation level of a Richmond Agitation-Sedation Scale (RASS) (-2)-(-3). The sedation was stopped when NIMV was discontinued.
A total of 60 patients, 42 (70.0%) male, and 18 (30.0%) female, with a mean age of 68 ± 11 years were included in the study. The mean APACHE II score was 20 ± 6. Dexmedetomidine was infused for a median of 25 h (loading dose of 0.2 mcg/kg for 10 min, maintained at 0.2-0.7 mcg/kg/h, titrated every 30 min). RASS score of all study group significantly improved at the 2 h of dexmedetomidine initiation (+3 vs. -2, = 0.01). A targeted sedation level was achieved in 92.5% of patients. Six (10.0%) patients developed bradycardia and 5 (8.3%) patients had hypotension. The mean NIMV application time was 23.4 ± 6.1 h. Seven (11.6%) patients experienced NIMV failure, all due to worsening pulmonary conditions, and required intubation and invasive ventilation. Fifty-three (88.3%) patients were successfully weaned from NIMV with dexmedetomidine sedation and discharged from ICU. The duration of NIMV application and ICU stay was shorter in NIMV succeded group (21.4 ± 3.2 vs. 29.9 ± 6.4; = 0.012).
Our study suggests that dexmedetomidine demonstrates effective sedation in patients with postoperative ARF during NIMV application after abdominal surgery. Dexmedetomidine can be considered safe and capable of improving NIMV success.
无创机械通气(NIMV)对术后急性呼吸衰竭(ARF)的疗效存在争议,且该患者群体中NIMV的失败率较高。在我们的研究中,我们假设在腹部大手术患者进行NIMV期间使用右美托咪定可降低NIMV失败率且无明显副作用。
纳入在我院普通外科重症监护病房(ICU)接受腹部大手术、术后发生ARF、接受NIMV(经口鼻面罩)及右美托咪定输注的患者的病历资料。调整输注速率以维持目标镇静水平,即里士满躁动 - 镇静量表(RASS)为(-2)-(-3)。当停止NIMV时停用镇静。
本研究共纳入60例患者,男性42例(70.0%),女性18例(30.0%),平均年龄68±11岁。急性生理与慢性健康状况评分系统(APACHE II)平均评分为20±6。右美托咪定输注时间中位数为25小时(负荷剂量0.2μg/kg,持续10分钟,维持剂量0.2 - 0.7μg/kg/h,每30分钟滴定一次)。在开始使用右美托咪定2小时时,所有研究组的RASS评分显著改善(从+3改善至 - 2,P = 0.01)。92.5%的患者达到目标镇静水平。6例(10.0%)患者出现心动过缓,5例(8.3%)患者出现低血压。NIMV平均应用时间为23.4±6.1小时。7例(11.6%)患者NIMV失败,均因肺部情况恶化,需要插管及有创通气。53例(88.3%)患者在右美托咪定镇静下成功撤机并从ICU出院。NIMV成功组的NIMV应用时间及ICU住院时间较短(21.4±3.2 vs. 29.9±6.4;P = 0.012)。
我们的研究表明,右美托咪定在腹部手术后NIMV应用期间对术后ARF患者具有有效的镇静作用。右美托咪定可被认为是安全的,并且能够提高NIMV的成功率。